chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain in extremity, Wrong product administered
Clinical narrative: Moderna pediatric dose administered to patient instead of Moderna bivalent booster; had sore arm after every mRNA shot; had headaches after every mRNA shot; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (had sore arm after every mRNA shot), HEADACHE (had headaches after every mRNA shot) and WRONG PRODUCT ADMINISTERED (Moderna pediatric dose administered to patient instead of Moderna bivalent booster) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR6965B) for COVID-19 prophylaxis.     No Medical History information was reported.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2022, received fifth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In October 2022, the patient experienced PAIN IN EXTREMITY (had sore arm after every mRNA shot) and HEADACHE (had headaches after every mRNA shot). On 25-Oct-2022, the patient experienced WRONG PRODUCT ADMINISTERED (Moderna pediatric dose administered to patient instead of Moderna bivalent booster). At the time of the report, PAIN IN EXTREMITY (had sore arm after every mRNA shot), HEADACHE (had headaches after every mRNA shot) and WRONG PRODUCT ADMINISTERED (Moderna pediatric dose administered to patient instead of Moderna bivalent booster) outcome was unknown.            No concomitant medication was reported.  Patient stated that she was scheduled to receive the Moderna COVID-19 bivalent vaccine on 25-Oct-2022, went to a local pharmacy, where she was assured that she would be receiving the Moderna bivalent vaccine. However, that night patient received a call from the pharmacy where it was stated that patient and her husband along with 200 other patients had received a dose from the pediatric vial instead of the bivalent vaccine. Doctor had told the patient to wait at least a month to get the next booster dose.  No treatment medication was reported.   This case was linked to US-MODERNATX, INC.-MOD-2022-665518, US-MODERNATX, INC.-MOD-2022-665512 (Linked Report). This case was linked to MOD-2022-665445 (Patient Link).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-665518:Husband cases- Bivalent dose, same reporter US-MODERNATX, INC.-MOD-2022-665512:Husband cases- Primary doses, same reporter
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Pain in extremity
Clinical narrative: both of us have had sore arm after every mRNA shot; both of us have had headaches after every mRNA shot; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PAIN IN EXTREMITY (both of us have had sore arm after every mRNA shot) and HEADACHE (both of us have had headaches after every mRNA shot) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (both of us have had sore arm after every mRNA shot) and HEADACHE (both of us have had headaches after every mRNA shot). At the time of the report, PAIN IN EXTREMITY (both of us have had sore arm after every mRNA shot) and HEADACHE (both of us have had headaches after every mRNA shot) outcome was unknown.            No concomitant medications were reported. No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2022-665445 (Linked Report). This case was linked to MOD-2022-665518 (Patient Link).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-665445:Wife cases-  (MOD-2022-665445-1st dose and MOD-2022-665505-Bivalent dose)
Sex: U
Vaccine: COVID19
Symptoms: Accidental underdose, No adverse event
Clinical narrative: Received 0.25ml of Bivalent booster instead of 0.5 ml; No Adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of ACCIDENTAL UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml).    No concomitant medication was reported.    Vaccination date was reported as 01-SEP-2022 to 26-OCT-2022. No treatment information was reported. This case contains information for the 1st of 20 patients described by the reporter.
Sex: U
Vaccine: COVID19
Symptoms: Accidental underdose, No adverse event
Clinical narrative: No adverse event; Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml; This spontaneous case was reported by a nurse and describes the occurrence of ACCIDENTAL UNDERDOSE (Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    In 2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. In 2022, the patient experienced ACCIDENTAL UNDERDOSE (Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml). No concomitant medications were reported. The patient received vaccine from a time period between 01-Sep-2022 to 26-Oct-2022. The reporter asked what to do next after the medication error incident occurred. No treatment information was reported. This case contains information for the second patient out of 20 adult patients as described by the reporter. This case was linked to US-MODERNATX, INC.-MOD-2022-665494 (E2B Linked Report).; Sender's Comments: US-MODERNATX, INC.-MOD-2022-665494:Same reporter.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Accidental underdose, No adverse event
Clinical narrative: No adverse event; Patient inadvertently received 0.25mL instead of 0.5mL of the Moderna Bivalent Booster; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (Patient inadvertently received 0.25mL instead of 0.5mL of the Moderna Bivalent Booster) and NO ADVERSE EVENT (No adverse event) in a 53-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 059F22A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .25 milliliter. On 14-Oct-2022, the patient experienced ACCIDENTAL UNDERDOSE (Patient inadvertently received 0.25mL instead of 0.5mL of the Moderna Bivalent Booster). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Patient inadvertently received 0.25mL instead of 0.5mL of the Moderna Bivalent Booster) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Patient inadvertently received 0.25mL instead of 0.5mL of the Moderna Bivalent Booster).    No concomitant medication information was provided.  No treatment medication was provided.
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Underdose
Clinical narrative: Received 0.25ml of Bivalent booster instead of 0.5 ml; No Adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event). At the time of the report, UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessment was provided for UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml).    It was reported as patient received 0.25ml of Bivalent Moderna COVID-19 vaccine instead of 0.5 ml and none of the patients are pregnant. No concomitant  and treatment information were reported by the reporter.   This case was linked to CMOD22-04360 (Linked Report).; Sender's Comments:  CMOD22-04360:CMOD22-04360 cross linked case
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product administration interrupted
Clinical narrative: Patient did not receive the second dose; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (Patient did not receive the second dose) and NO ADVERSE EVENT (No adverse event) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032h21a) for COVID-19 prophylaxis.     No Medical History information was reported.    On 16-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Patient did not receive the second dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (Patient did not receive the second dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTRATION INTERRUPTED (Patient did not receive the second dose).    No concomitant medications were provided. No treatment medication was provided.
Age: 15.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: No adverse event; Received Expired Bivalent booster beyond 12 hours post puncture; Vaccine administered more than 12 hours after the initial vial puncture.; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent booster beyond 12 hours post puncture), PRODUCT STORAGE ERROR (Vaccine administered more than 12 hours after the initial vial puncture.) and NO ADVERSE EVENT (No adverse event) in a 15-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 064A22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 27-Oct-2022 at 11:30 AM, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 27-Oct-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent booster beyond 12 hours post puncture) and PRODUCT STORAGE ERROR (Vaccine administered more than 12 hours after the initial vial puncture.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent booster beyond 12 hours post puncture), PRODUCT STORAGE ERROR (Vaccine administered more than 12 hours after the initial vial puncture.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent booster beyond 12 hours post puncture) and PRODUCT STORAGE ERROR (Vaccine administered more than 12 hours after the initial vial puncture.).    No concomitant medication details was reported. It was reported that individual vial was used and vial size was 2.5ml. On 26-OCT -2022 the vial was initially stored in the refrigerator. Vial was first punctured on 26-OCT-2022 at 10AM. Vial was in the refrigerator the entire time for greater than 24 hours. Vial exposed to room temperature for greater than 24 hours. The vial did not undergo any temperature excursions.  No treatment medication details was reported.   This case was linked to US-MODERNATX, INC.-MOD-2022-665658 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-665658:Same reporter
Age: 14.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product administered to patient of inappropriate age
Clinical narrative: No adverse event; Received Expired Bivalent booster beyond 12 hours post puncture; 14 years patient received Expired Bivalent booster Moderna; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent booster beyond 12 hours post puncture), PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (14 years patient received Expired Bivalent booster Moderna) and NO ADVERSE EVENT (No adverse event) in a 14-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 064A22A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Oct-2022 at 2:40 AM, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 27-Oct-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent booster beyond 12 hours post puncture) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (14 years patient received Expired Bivalent booster Moderna). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent booster beyond 12 hours post puncture), PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (14 years patient received Expired Bivalent booster Moderna) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Received Expired Bivalent booster beyond 12 hours post puncture) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (14 years patient received Expired Bivalent booster Moderna).    Concomitant medications details were not reported by the reporter. Vial size was reported as 2.5 ml. On 26-OCT-2022, vial was initially stored in refrigerator. Vial was in the refrigerator the entire time for >24 hours. Vial was first punctured on 26-OCT-2022 at 10 A.M. Vial did not undergo any temperature excursions. Treatment details was not reported by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-665655 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-665655:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Accidental underdose, No adverse event
Clinical narrative: No Adverse event; Patient received 0.25ml of Bivalent booster instead of 0.5 ml; This spontaneous case was reported by a nurse and describes the occurrence of ACCIDENTAL UNDERDOSE (Patient received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    In 2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. In 2022, the patient experienced ACCIDENTAL UNDERDOSE (Patient received 0.25ml of Bivalent booster instead of 0.5 ml). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Patient received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Patient received 0.25ml of Bivalent booster instead of 0.5 ml).    No concomitant information was reported. This case was reported for 11th patient out of 20 patients. It was reported that none of the patients were pregnant. No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-665494 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-665494:
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product administration interrupted
Clinical narrative: Patient did not return to get the 2nd dose of Moderna; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (Patient did not return to get the 2nd dose of Moderna) and NO ADVERSE EVENT (No adverse event) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunization.     No Medical History information was reported.    On 17-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Patient did not return to get the 2nd dose of Moderna) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (Patient did not return to get the 2nd dose of Moderna) and NO ADVERSE EVENT (No adverse event) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTRATION INTERRUPTED (Patient did not return to get the 2nd dose of Moderna).    Concomitant product use was not provided by the reporter.  It was reported that the patient did not return to get the second dose of Moderna. Patient did not had adverse reactions.  Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Accidental underdose, No adverse event
Clinical narrative: Received 0.25ml of Bivalent booster instead of 0.5 ml; No Adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of ACCIDENTAL UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Received 0.25ml of Bivalent booster instead of 0.5 ml).    Concomitant medications were not reported.  None of the patients are pregnant.  No treatment information was provided by the reporter.  This case is reported for 12th  patient out of 20 patients.
Sex: U
Vaccine: COVID19
Symptoms: Accidental underdose, No adverse event
Clinical narrative: No adverse event; Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml; This spontaneous case was reported by a nurse and describes the occurrence of ACCIDENTAL UNDERDOSE (Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    In 2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. In 2022, the patient experienced ACCIDENTAL UNDERDOSE (Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Patient received 0.25 ml of bivalent Moderna COVID-19 vaccine instead of 0.5 ml).    No concomitant medications were reported.  The patient received vaccine from a time period between 01-Sep-2022 to 26-Oct-2022. The reporter asked what to do next after the medication error incident occurred.  No treatment information was reported.  This case contains information for the seventeenth patient out of 20 adult patients as described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-665494 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-665494:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Accidental underdose, No adverse event
Clinical narrative: Patient received 0.25ml of Bivalent Moderna COVID-19 vaccine instead of 0.5 ml; No Adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of ACCIDENTAL UNDERDOSE (Patient received 0.25ml of Bivalent Moderna COVID-19 vaccine instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (Patient received 0.25ml of Bivalent Moderna COVID-19 vaccine instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Patient received 0.25ml of Bivalent Moderna COVID-19 vaccine instead of 0.5 ml) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Patient received 0.25ml of Bivalent Moderna COVID-19 vaccine instead of 0.5 ml).    No concomitant information was reported.  It was reported that none of the patients were pregnant.  No treatment information was provided.  This case was reported for 15th patient out of 20 patients.
Sex: F
Vaccine: COVID19
Symptoms: Illness, Weight
Clinical narrative: Getting ready to get Pfizer Covid 19 Booster Vaccine, because every time got Moderna Vaccine, got sick.; This spontaneous case was reported by a patient and describes the occurrence of ILLNESS (Getting ready to get Pfizer Covid 19 Booster Vaccine, because every time got Moderna Vaccine, got sick.) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Concurrent medical conditions included Thyroid stimulating hormone deficiency (did not have a Thyroid). Concomitant products included LEVOTHYROXINE SODIUM (LEVOXYL) and LEVOTHYROXINE SODIUM (SYNTHROID) for Thyroid stimulating hormone deficiency.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Getting ready to get Pfizer Covid 19 Booster Vaccine, because every time got Moderna Vaccine, got sick.). At the time of the report, ILLNESS (Getting ready to get Pfizer Covid 19 Booster Vaccine, because every time got Moderna Vaccine, got sick.) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2022, Weight: Since Jan-2022, put on about 15 pounds.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Till 24-Oct-2022, the patient had been waiting for Levoxyl 112 micrograms to arrive from backorder since 19-Sep-2022. The patient took 112 microgram dose of Levoxyl. Patient did not had thyroid, dependent on Levoxyl to survive. She used Levoxyl because was sensitive to inconsistencies in dosage in other product. Since 2015 Levoxyl had been on backordered many times, which doctor warned the patient about it. She had taken Levoxyl 125 mcg tablets, nibbling off dose and throwing the rest away. When took Synthroid, levels were up and down. The patient was getting ready to get Pfizer Covid 19 Booster Vaccine, because every time she took Moderna vaccine, she got sick. She she might get Moderna Vaccine again. However, she did not know about it. The point was that could not get Levoxyl medication. She began Levoxyl  7 years back. Started as soon as went on Levoxyl, was warned about difficulty to get Levoxyl. Was just given 5 Levoxyl. She was getting Levoxyl off and on for last 6 weeks. Since Jan-2022, had  put on about 15 pounds, but currently the dosage was 112 micrograms Levoxyl. She had previously taken Levoxyl 125mcg tablets, nibbling off dose and throwing the rest away. As she had not been able to consistently get 112 micrograms of Levoxyl, but had leftover 125 micrograms, nibbles off a little bit and spits out and takes pill to try to get as close as possible to 112 micrograms. She could not get blood tests because would be inconsistent and would not be able to prescribe new dosage, would not be able to estimate.  No treatment information was provided.   Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Feeling abnormal, SARS-CoV-2 test
Clinical narrative: got COVID; felt "funnier than I usually do"; This spontaneous case was reported by a patient and describes the occurrence of FEELING ABNORMAL (felt "funnier than I usually do") and COVID-19 (got COVID) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 18-Oct-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In October 2022, the patient experienced FEELING ABNORMAL (felt "funnier than I usually do"). On 20-Oct-2022, the patient experienced COVID-19 (got COVID). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, FEELING ABNORMAL (felt "funnier than I usually do") and COVID-19 (got COVID) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Oct-2022, SARS-CoV-2 test: Positive.         Concomitant product use was not provided by the reporter. Patient interpreted that COVID-19 infection may happened while Patient sat for half an hour for  the 5th dose . Patient past vaccination included Moderna Vaccination.
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; some were inadvertently administered 0.5ml of Moderna Magenta Vial for ages 6 months through 5 years instead of Moderna bivalent booster; This spontaneous case was reported by a nurse and describes the occurrence of WRONG PRODUCT ADMINISTERED (some were inadvertently administered 0.5ml of Moderna Magenta Vial for ages 6 months through 5 years instead of Moderna bivalent booster) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1414B) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Oct-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 15-Oct-2022, the patient experienced WRONG PRODUCT ADMINISTERED (some were inadvertently administered 0.5ml of Moderna Magenta Vial for ages 6 months through 5 years instead of Moderna bivalent booster). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (some were inadvertently administered 0.5ml of Moderna Magenta Vial for ages 6 months through 5 years instead of Moderna bivalent booster) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (some were inadvertently administered 0.5ml of Moderna Magenta Vial for ages 6 months through 5 years instead of Moderna bivalent booster).    Concomitant medication information was not provided.  It was reported that out of the 36 patients who were in a COVID vaccine clinic on 15-Oct-2022 for receiving the bivalent booster doses, some were inadvertently administered 0.5 ml of Moderna lot of Magenta vial that was intended for ages 6 months through 5 years, and some were given the correct Moderna Bivalent vaccine from blue cap grey label vial.   Unfortunately the wrong vials were grabbed in the midst of administration and the nurse had not noticed at what point the error occurred. They understood that if the patients were given the pediatric doses, they could administer the correct bivalent formulation to those patients, but they had no way of knowing exactly who it would be. On the other hand if the patient did actually receive the correct bivalent dose, then another dose would not be indicated for them.  It was reported that no adverse events were reported after vaccine was administered.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-Oct-2022: Live follow up receive contain : updated event verbatim, and updated narrative.
Age: 75.0
Sex: M
Vaccine: COVID19, FLUX
Symptoms: Nasopharyngitis, Oxygen saturation
Clinical narrative: Cold; This spontaneous case was reported by a patient and describes the occurrence of NASOPHARYNGITIS (Cold) in a 75-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 immunization.    Co-suspect products included non-company products TREPROSTINIL SODIUM (TYVASO) for Secondary pulmonary arterial hypertension and INFLUENZA VACCINE (FLU [INFLUENZA VACCINE]) for Influenza immunisation.    Concurrent medical conditions included Pulmonary arterial hypertension. Concomitant products included NINTEDANIB ESILATE (OFEV) for an unknown indication.   In 2022, the patient started TREPROSTINIL SODIUM (TYVASO) (Inhalation use) 16 microgram four times per day. In 2022, TREPROSTINIL SODIUM (TYVASO) (Inhalation use) dosage was changed to 32 microgram four times per day. On 19-Sep-2022, TREPROSTINIL SODIUM (TYVASO) (Inhalation use) dosage was changed to at an unspecified dose. On 24-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form and dose of INFLUENZA VACCINE (FLU [INFLUENZA VACCINE]) (unknown route) 1 dosage form. On 24-Oct-2022, the patient experienced NASOPHARYNGITIS (Cold). The patient was treated with OXYGEN at a dose of 2 liters as needed. At the time of the report, NASOPHARYNGITIS (Cold) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 25-Oct-2022, Oxygen saturation: 83-85%.         It was reported that on an unreported date in 2022, the patient was experiencing headaches with Tyvaso DPI (headache) that relieved with Tylenol (paracetamol) and he had missed a few doses in the last 2 weeks of Tyvaso (product dose omission issue). Action taken with Tyvaso DPI was not reported for the event of headache. At the time of reporting, the outcome of headache was resolved on an unreported date in 2022. The reporter's causality for the event of headache with Tyvaso DPI was considered to be possibly related. On 25 Oct 2022, 1 month 7 days, after initiating Tyvaso DPI, his oxygen saturations was dropping down to 83 to 85% (oxygen saturation decreased). He was using oxygen 2 liters as needed. He was having headaches with Tyvaso DPI increase (headache previously reported). Action taken with Tyvaso DPI was not reported for the events of nasopharyngitis and oxygen saturation decreased. At the time of reporting, the outcome of nasopharyngitis, oxygen saturation decreased, and headache was unknown.
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022; given vaccine which was beyond the 30 day use by date; administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022), PRODUCT STORAGE ERROR (administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022) and NO ADVERSE EVENT (given vaccine which was beyond the 30 day use by date) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) (batch no. 053B22A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Oct-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 26-Oct-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022) and NO ADVERSE EVENT (given vaccine which was beyond the 30 day use by date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022), PRODUCT STORAGE ERROR (administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022) and NO ADVERSE EVENT (given vaccine which was beyond the 30 day use by date) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (given vaccine which was beyond the 30 day use by date) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022) and PRODUCT STORAGE ERROR (administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26Oct2022).    No concomitant drug were reported.  Initial date the vial was placed in the refrigerator on 18-Aug-2022. Pharmacist reported that they administered one dose of the monovalent vaccine which was beyond the 30 day use by date on 26-Oct-2022.   Manufacturing expiration date was not looked up.  Vial size was reported as 5.5ml.  The vial did not undergo any temperature excursions. No treatment drug were reported.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Only sore for a day after previous Moderna shots; This spontaneous case was reported by a patient and describes the occurrence of PAIN (Only sore for a day after previous Moderna shots) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN (Only sore for a day after previous Moderna shots). At the time of the report, PAIN (Only sore for a day after previous Moderna shots) had resolved.            No concomitant information was reported.  The patient stated that he only sore for a day after previous Moderna shots.  No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-666024 (Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-666024:Crosslink-MOD22-028059(Son case)
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fall, Immunisation reaction, Mobility decreased, Muscular weakness, Urinary incontinence
Clinical narrative: was bladder incontinent; had such and an extreme reaction; lost all their muscle strength; could not move; slid off the bed and was sitting on the floor; This spontaneous case was reported by a patient and describes the occurrence of URINARY INCONTINENCE (was bladder incontinent), IMMUNISATION REACTION (had such and an extreme reaction), MUSCULAR WEAKNESS (lost all their muscle strength), MOBILITY DECREASED (could not move) and FALL (slid off the bed and was sitting on the floor) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027A21A and 013M20A) for COVID-19 prophylaxis.     The patient's past medical history included Leukemia (has had leukemia before and that it was more important to get the vaccine). Concurrent medical conditions included Diabetes.   On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced URINARY INCONTINENCE (was bladder incontinent), IMMUNISATION REACTION (had such and an extreme reaction), MUSCULAR WEAKNESS (lost all their muscle strength), MOBILITY DECREASED (could not move) and FALL (slid off the bed and was sitting on the floor). At the time of the report, URINARY INCONTINENCE (was bladder incontinent), IMMUNISATION REACTION (had such and an extreme reaction), MUSCULAR WEAKNESS (lost all their muscle strength), MOBILITY DECREASED (could not move) and FALL (slid off the bed and was sitting on the floor) outcome was unknown.            Concomitant products included diabetes medication.  After the  second dose patient had such and an extreme reaction and went to the hospital in an ambulance. Patient lost all their muscle strength, slid off the bed and was sitting on the floor, could nott move and had bladder incontinent.  Patient said that 4 hours later, was sent home from the hospital after receiving IV fluids.   This case was linked to MOD-2022-666108 (Patient Link).
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Muscular weakness, Urinary incontinence
Clinical narrative: was bladder incontinent; had such and an extreme reaction; lost all their muscle strength; could not move; slid off the bed and was sitting on the floor; This spontaneous case was reported by a patient and describes the occurrence of URINARY INCONTINENCE (was bladder incontinent), IMMUNISATION REACTION (had such and an extreme reaction), MUSCULAR WEAKNESS (lost all their muscle strength), MOBILITY DECREASED (could not move) and FALL (slid off the bed and was sitting on the floor) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027A21A and 013M20A) for COVID-19 prophylaxis.     The patient's past medical history included Leukemia (has had leukemia before and that it was more important to get the vaccine). Concurrent medical conditions included Diabetes.   On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced URINARY INCONTINENCE (was bladder incontinent), IMMUNISATION REACTION (had such and an extreme reaction), MUSCULAR WEAKNESS (lost all their muscle strength), MOBILITY DECREASED (could not move) and FALL (slid off the bed and was sitting on the floor). At the time of the report, URINARY INCONTINENCE (was bladder incontinent), IMMUNISATION REACTION (had such and an extreme reaction), MUSCULAR WEAKNESS (lost all their muscle strength), MOBILITY DECREASED (could not move) and FALL (slid off the bed and was sitting on the floor) outcome was unknown.            Concomitant products included diabetes medication.  After the  second dose patient had such and an extreme reaction and went to the hospital in an ambulance. Patient lost all their muscle strength, slid off the bed and was sitting on the floor, could nott move and had bladder incontinent.  Patient said that 4 hours later, was sent home from the hospital after receiving IV fluids.   This case was linked to MOD-2022-666108 (Patient Link).
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fall, Immunisation reaction, Mobility decreased, Muscular weakness, Urinary incontinence
Clinical narrative: lost all their muscle strength; bladder incontinent; This spontaneous case was reported by a patient and describes the occurrence of MUSCULAR WEAKNESS (lost all their muscle strength) and URINARY INCONTINENCE (bladder incontinent) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031H21A, 027A21A and 013M20A) for COVID-19 prophylaxis.     The patient's past medical history included Leukemia (had leukemia). Concurrent medical conditions included Diabetes.   On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MUSCULAR WEAKNESS (lost all their muscle strength) and URINARY INCONTINENCE (bladder incontinent). At the time of the report, MUSCULAR WEAKNESS (lost all their muscle strength) and URINARY INCONTINENCE (bladder incontinent) had resolved.            It was reported that patient took medication for diabetes.  It was reported that after booster patient had incontinence and loss muscle strength but it subsided in a few hours, was down and out for a couple of days. No treatment medication were provided.   This case was linked to MOD-2022-666049.